|
2022 Journal Article Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: results from the ANDROMEDA studySanchorawala, Vaishali, Palladini, Giovanni, Minnema, Monique C., Jaccard, Arnaud, Lee, Hans C., Gibbs, Simon, Mollee, Peter, Venner, Christopher, Lu, Jin, Schönland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, María Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Gries, Katharine S., Fastenau, John, Tran, Nam Phuong, Qin, Xiang, Vasey, Sandra Y., Weiss, Brendan M., Vermeulen, Jessica ... Wechalekar, Ashutosh D. (2022). Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: results from the ANDROMEDA study. American Journal of Hematology, 97 (6), 719-730. doi: 10.1002/ajh.26536 |
|
2022 Journal Article An individualized exercise intervention for people with multiple Myeloma—study protocol of a randomized waitlist-controlled trialNicol, Jennifer L., Woodrow, Carmel, Cunningham, Brent J., Mollee, Peter, Weber, Nicholas, Smith, Michelle D., Nicol, Andrew J., Gordon, Louisa G., Hill, Michelle M. and Skinner, Tina L. (2022). An individualized exercise intervention for people with multiple Myeloma—study protocol of a randomized waitlist-controlled trial. Current Oncology, 29 (2), 901-923. doi: 10.3390/curroncol29020077 |
|
2022 Journal Article Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelinesSanchorawala, Vaishali, Boccadoro, Mario, Gertz, Morie, Hegenbart, Ute, Kastritis, Efstathios, Landau, Heather, Mollee, Peter, Wechalekar, Ashutosh and Palladini, Giovanni (2022). Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid, 29 (1), 1-7. doi: 10.1080/13506129.2021.2002841 |
|
2022 Journal Article Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)Kalff, Anna, Khong, Tiffany, Ramachandran, Malarmathy, Joy Ho, P., Mollee, Peter, D’Rozario, James, Taylor, Kerry, Estell, Jane, Norton, Sam, Kemp, Roslyn, Mitchell, Andrew J., Reynolds, John, Kennedy, Nola, Quach, Hang and Spencer, Andrew (2022). Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Haematologica, 107 (1), 321-325. doi: 10.3324/haematol.2021.278655 |
|
2022 Conference Publication Predictors of outcomes in patients with ATTRwt cardiac amyloidosisMew, T., Mollee, P. and Korczyk, D. (2022). Predictors of outcomes in patients with ATTRwt cardiac amyloidosis. 70th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Gold Coast, QLD Australia, 11-14 August 2022. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2022.06.115 |
|
2021 Journal Article The role of a routine bone marrow biopsy in autoimmune hemolytic anemia for the detection of an underlying lymphoproliferative disorderCampbell, Ashlea, Podbury, Bridget, Yue, Mimi, Mollee, Peter, Bird, Robert and Hapgood, Greg (2021). The role of a routine bone marrow biopsy in autoimmune hemolytic anemia for the detection of an underlying lymphoproliferative disorder. HemaSphere, 6 (1), e674-e674. doi: 10.1097/hs9.0000000000000674 |
|
2021 Journal Article Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertionsJones, M., Okano, S., Looke, D., Kennedy, G., Pavilion, G., Clouston, J., Van Kuilenburg, R., Geary, A., Joubert, W., Eastgate, M. and Mollee, P. (2021). Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertions. Journal of Hospital Infection, 118, 70-76. doi: 10.1016/j.jhin.2021.10.008 |
|
2021 Conference Publication Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)Li Chai, Khai, Wellard, Cameron, Moore, Elizabeth M., Augustson, Bradley, Bapat, Akshay, Blacklock, Hilary Anne, Cooke, Rachel Elizabeth, Forsyth, Cecily, Hamad, Nada, Harrison, Simon J., Ho, Phobe Joy, Hocking, Jay, Kerridge, Ian H., King, Tracy, McCaughan, Georgia J., Mollee, Peter, Morrissey, Orla, Murphy, Nicholas E., Quach, Hand, Tan, Xuan Ni, Wong, Kimberly, Spencer, Andrew, Wood, Erica M. and McQuilten, Zoe (2021). Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-147622 |
|
2021 Conference Publication Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA StudyComenzo, Raymond, Palladini, Giovanni, Kastritis, Efsthathios, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Dispenzieri, Angela, Lee, Hans C., Sanchorawala, Vaishali, Gibbs, Simon D., Mollee, Peter, Venner, Chris P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Teresa Cibeira, M., Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Tran, Nam Phuong, Xin, Xiang, Khaled, Samer, Vermeulen, Jessica and Merlini, Giampaolo (2021). Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study. 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. WASHINGTON: AMER SOC HEMATOLOGY. doi: 10.1182/blood-2021-146820 |
|
2021 Conference Publication A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)Mollee, Peter, Reynolds, John, Janowski, Wojciech, Quach, Hang, Campbell, Philip, Gibbs, Simon D., Lee, Sophie, D'Rozario, James, Taylor, Kerry, Cochrane, Tara, Wallington-Beddoe, Craig Thomas, Kwok, Fiona, Weber, Nicholas, Kerridge, Ian H., Weston, Helen, Ho, P. Joy, Horvath, Noemi, Yuen, Flora and Spencer, Andrew (2021). A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-152500 |
|
2021 Journal Article Management and outcomes of diffuse large B-cell lymphoma post-transplant lymphoproliferative disorder in the era of PET and Rituximab: a multicenter study from the Australasian Lymphoma AllianceBoyle, Stephen, Tobin, Joshua W. D., Perram, Jacinta, Hamad, Nada, Gullapalli, Veena, Barraclough, Allison, Singaraveloo, Lydia, Han, Min-Hi, Blennerhassett, Richard, Nelson, Niles, Johnston, Anna M., Talaulikar, Dipti, Karpe, Krishna, Bhattacharyya, Abir, Cheah, Chan Yoon, Subramoniapillai, Elango, Bokhari, Waqas, Lee, Cindy, Hawkes, Eliza A., Jabbour, Andrew, Strasser, Simone, Chadban, Steven J., Brown, Christina, Mollee, Peter and Hapgood, Greg (2021). Management and outcomes of diffuse large B-cell lymphoma post-transplant lymphoproliferative disorder in the era of PET and Rituximab: a multicenter study from the Australasian Lymphoma Alliance. HemaSphere, 5 (11) e648, 1-8. doi: 10.1097/hs9.0000000000000648 |
|
2021 Journal Article Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma AustraliaCreeper, Katherine, Augustson, Bradley, Kusel, Kieran, Fulham, Michael J., Ho, Joy, Quach, Hang, Mollee, Peter, Weber, Nicholas, Talaulikar, Dipti, Johnston, Anna, Murphy, Nick, Joshua, Douglas, Ward, Christopher, Ling, Silvia, Gibson, John, Szer, Jeff, Harrison, Simon, Zannettino, Andrew, Jaksic, Wilfrid, Lee, Cindy, Spencer, Andrew, Kalff, Anna, Szabo, Ferenc, Romeril, Ken, Chan, Henry, Gibbs, Simon, Horvath, Noemi and Prince, H. Miles (2021). Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 51 (10), 1707-1712. doi: 10.1111/imj.15457 |
|
2021 Journal Article Daratumumab-based treatment for immunoglobulin light-chain amyloidosisKastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Lee, Hans C., Sanchorawala, Vaishali, Gibbs, Simon, Mollee, Peter, Venner, Christopher P., Lu, Jin, Schönland, Stefan, Gatt, Moshe E., Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Huart, Antoine, Dimopoulos, Meletios A., Bhutani, Divaya, Waxman, Adam J., Goodman, Stacey A., Zonder, Jeffrey A. ... Comenzo, Raymond L. (2021). Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. New England Journal of Medicine, 385 (1), 46-58. doi: 10.1056/NEJMoa2028631 |
|
2021 Journal Article Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based inductionBoyle, Stephen, Wellard, Cameron, Moore, Elizabeth M., Blacklock, Hilary, Harrison, Simon J., Ho, Phoebe Joy, Hocking, Jay, McQuilten, Zoe K., Quach, Hang, Spearing, Ruth, Wood, Erica M., Spencer, Andrew and Mollee, Peter (2021). Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. European Journal of Haematology, 107 (4) ejh.13677, 497-499. doi: 10.1111/ejh.13677 |
|
2021 Journal Article The myeloma landscape in Australia and New Zealand: the first 8 years of the Myeloma and Related Diseases Registry (MRDR)Bergin, Krystal, Wellard, Cameron, Moore, Elizabeth, McQuilten, Zoe, Blacklock, Hilary, Harrison, Simon J., Ho, P. Joy, King, Tracy, Quach, Hang, Mollee, Peter, Walker, Patricia, Wood, Erica and Spencer, Andrew (2021). The myeloma landscape in Australia and New Zealand: the first 8 years of the Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 21 (6), e510-e520. doi: 10.1016/j.clml.2021.01.016 |
|
2021 Conference Publication A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, SealandQuach, Hang, Lasica, Masa, Routledge, David, Kalff, Anna, Lim, Andrew, Low, Michael, Estell, Jane A., Sidiqi, M. Hasib, Campbell, Philip, Eek, Richard Wilhelm, Lai, Hock C., McCaughan, Georgia J., D'Rozario, James, Browlett, Peter, Rajagopal, Rajeev, Heenan, Jessica, Murphy, Nicholas E., Renwick, William, Huan, Georgina and Mollee, Peter (2021). A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand. Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 04-08, 2021. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2021.39.15_suppl.TPS8055 |
|
2021 Journal Article Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)Bergin, Krystal, Wellard, Cameron, Augustson, Bradley, Cooke, Rachel, Blacklock, Hilary, Harrison, Simon J., Ho, Joy, King, Tracy, Quach, Hang, Mollee, Peter, Walker, Patricia, Moore, Elizabeth, McQuilten, Zoe, Wood, Erica, Spencer, Andrew and on behalf of the Australian and New Zealand Myeloma and Related Diseases Registry (2021). Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation, 56 (10), 2533-2543. doi: 10.1038/s41409-021-01308-8 |
|
2021 Journal Article The Clinical Impact of Proteomics in Amyloid TypingHill, Michelle M., Dasari, Surendra, Mollee, Peter, Merlini, Giampaolo, Costello, Catherine E., Hazenberg, Bouke P.C., Grogan, Martha, Dispenzieri, Angela, Gertz, Morie A., Kourelis, Taxiarchis and McPhail, Ellen D. (2021). The Clinical Impact of Proteomics in Amyloid Typing. Mayo Clinic Proceedings, 96 (5), 1122-1127. doi: 10.1016/j.mayocp.2020.12.002 |
|
2021 Journal Article Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel findingMar, Ethan, Taylor, Kerry and Mollee, Peter (2021). Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding. BMJ Case Reports, 14 (4) e240631, 1-1. doi: 10.1136/bcr-2020-240631 |
|
2021 Journal Article Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocolUllman, Amanda J., August, Deanne, Kleidon, Tricia, Walker, Rachel, Marsh, Nicole M., Bulmer, Andrew, Pearch, Benjamin, Runnegar, Naomi, Schults, Jessica A., Leema, Joanne, Lee-Archer, Paul, Biles, Cathy, Southam, Katrina, Gibson, Victoria, Byrnes, Joshua, Ware, Robert S., Chopra, Vineet, Coulthard, Alan, Mollee, Peter, Rickard, Claire M. and Harris, Patrick N. A. (2021). Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocol. BMJ Open, 11 (4) e042475, 1-7. doi: 10.1136/bmjopen-2020-042475 |
